KR20130133563A - Pharmaceutical composition or functional food for promoting oxidation of fatty acid containing styela clava extract - Google Patents

Abstract

The present invention relates to a composition for oxidation of fatty acid or a pharmaceutical composition or a functional health food for alleviating obesity, hyperlipidemia, insulin resistance syndrome, or metabolic syndrome, containing a Styela clava extract and, more specifically, to a Styela clava extract according to the present invention which has an effect of inhibiting fatty acid synthesis by suppressing the expression of SREBP-1c, fatty acid synthase (FAS), and ACC and promotes oxidation of fatty acid by downregulation of ACC and upregulation of CPT-1. [Reference numerals] (AA) Styela clava extract

Description

[0001] The present invention relates to a pharmaceutical composition for accelerating fatty acid oxidation or a functional food containing the extract of Chrysanthemum morifolium,

The present invention relates to a composition containing Rhizome extract and its use.

The CPT-1 (Carnitine palmitoyl trnasferase-1) enzyme is a protein in the intracellular mitochondria, which transports long-chain fatty acids into the mitochondria. This enzyme is known to be involved in the rate determining step in the oxidation of long chain fatty acids in intracellular mitochondria.

It is known that increasing the expression of CPT-1 in cell-level and animal-level experiments increases the consumption of energy by promoting the oxidation of fatty acids. It is known that hypertriglycerid-induced hyperlipidemia is improved and insulin resistance is increased by increasing CPT-1 expression in obesity-induced rats through the administration of high fat diets (CT Cramer et al., Progress in Lipid Research , 40, pp 231-268, 2001)

On the other hand, various diseases such as obesity, hyperlipemia, insulin resistance syndrome or metabolic syndrome may develop due to inhibition of fatty acid oxidation, but it has not been reported that it has been possible to improve the above-mentioned diseases by using the extract of Chrysanthemum morifolium.

Accordingly, a problem to be solved by the present invention is to provide a composition for oxidizing fatty acids or a pharmaceutical composition for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome or a health functional food by using the extract of Chrysanthemum morifolium.

In order to solve the above-described problems, the present invention provides a composition for promoting fatty acid oxidation, which comprises an extract of Chrysanthemum morifolium as an active ingredient. The present invention also provides a pharmaceutical composition for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, and a health functional food, characterized by comprising a middelex extract as an active ingredient. More specifically, the present invention provides a pharmaceutical composition and a health functional food for promoting fatty acid oxidation by activating CPT-1, obesity, hyperlipidemia, insulin resistance syndrome, or metabolic syndrome improvement by the hypermodern extract. That is, the present invention provides medicinal uses of the extract of Chrysanthemum morifolium.

In the present invention, the health functional food refers to all foods manufactured or processed using raw materials or ingredients having useful functionality, and include all of health supplements, functional foods, nutrients, supplements, and the like.

The present invention also relates to a method for producing (S1) a process for producing a fermented milk, comprising the steps of: And (S2) centrifuging the obtained extract to obtain a supernatant. The present invention provides a method for enhancing the fatty acid oxidation activity through the extract of Chrysanthemum morifolium.

In the present invention, Styela clava used as a component having a fatty acid oxidation promoting activity is a marine creature belonging to a crustacean animal and a croaker animal. As a result, the inventors of the present invention have found that the inhibition of fatty acid synthesis and the promotion of fatty acid oxidation And completed the present invention. More specifically, the extract according to the present invention inhibits the expression of SREBP-1c (Sterol regulatory elementary-binding protein-1c), FAS (Fatty Acid Synthase) and ACC (Acetyl-CoA carboxylase) In particular, the inhibition of the expression of ACC and the expression of CPT-1 (Carnitine palmitoyl transferase-1) can be promoted, thereby promoting the oxidation of fatty acids.

The present invention relates to a composition for promoting fatty acid oxidation, a composition for promoting fatty acid oxidation, a pharmaceutical composition for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome or a health functional food. It is worth it.

SREBPs (Sterol regulatory elementary-binding protein) is an important transcriptional activator that regulates fatty acid and cholesterol synthesis in the liver by activating enzymes involved in the pathway for the biosynthesis of fatty acids and cholesterol. SREBP-1c has been shown to inhibit FAS (Fatty acid synthase), ACC (Acetyl-CoA carboxylase), malic enzyme and the like. ACC is a rate-regulating enzyme involved in the biosynthesis of fatty acids in liver and other tissues. Malonyl-CoA, a product of ACC, is a precursor of fatty acid biosynthesis and an enzyme that inhibits the oxidation of fatty acids in mitochondria. Malonyl-CoA inhibits CPT-1 (Carnitine palmitoyl transferase-1), which regulates the transport of long-chain acylcarnitines (LCAC) into the mitochondria, and decreases malonyl-CoA consequently inhibits CPT-1 The effect is decreased and the fatty acid oxidation is increased.

The inventors of the present invention have confirmed that the middendout extract inhibits the expression of SREBP-1c, FAS and ACC and increases the expression of CPT-1. From the effect of accelerating the oxidation activity of fatty acid by CPT-1 activation of the extract of Chrysanthemum morifolium, it can be known that the extract of Chrysanthemum morifolium can be used for obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome improvement.

Insulin resistance means that the tissue response to insulin action is reduced, which is called insulin resistance syndrome or metabolic syndrome. Insulin resistance syndrome refers to a phenomenon that occurs in one person, such as diabetes mellitus or dyslipidemia, due to insulin resistance. Metabolic syndrome refers to a case in which risk factors are clustered in one person, including obesity, which is well- Quot; It is known that insulin resistance may be caused by insulin action induced by the increase of free fatty acids and by competitive inhibition of glucose metabolism (Kim, YK et al., Insulin resistance and free fatty acids, BRIC BioWave Vol.5 No.6 2003 , pp. 5.) The extract according to the present invention can be used for the improvement, treatment and prevention of insulin resistance syndrome and metabolic syndrome by promoting fatty acid oxidation.

The extract according to the present invention means the extract obtained by a conventional extraction method in the field of the present invention.

The hemi-extracts used in the present invention can be extracted by using a suitable solvent such as water, methanol, ethanol, butanol, chloroform, dichloromethane, hexane, ethyl acetate or the like which is used in a conventional solvent extraction method after pulverizing dried hemi- And any extraction method may be used as long as it is an extract showing the obesity suppressing effect according to the present invention. However, preferably, ethanol is used as an extraction solvent.

The extract according to the present invention can be used as a method for achieving the object of the present invention, such as a pharmaceutical composition for promoting fatty acid oxidation, obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, or a health functional food.

To achieve the object of promoting fatty acid oxidation, the pharmaceutical composition of the present invention may be administered at a daily dose of about 0.01 mg / kg to about 10 g / kg, and may be administered at a dose of about 0.1 mg / kg to about 1 g / kg Lt; / RTI > For convenience, the total daily dose may be divided as needed and divided into several doses throughout the day. However, the dosage may vary depending on the administration route and formulation, the patient's condition (age, sex, weight, etc.), the severity of the condition being treated, the purity and content of the extract,

The active ingredient of the pharmaceutical composition according to the present invention can be administered by any of oral or parenteral administration. Parenteral administration includes intravenous injection, rectal administration and the like.

The pharmaceutical composition according to the present invention may be a solid preparation, a semisolid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like. Examples of the semi-solid preparation include a cream, a lotion, an emulsifier, a liniment, and the like, but the present invention is not limited thereto, and can be produced by adding a suitable colorant, a flavoring agent, a stabilizer, a tackifier, a surfactant, and the like. Examples of the liquid preparation include water, alcohols, solutions such as solutions of propylene glycol, suspensions, emulsions and the like, but not limited thereto, and they can be prepared by adding appropriate coloring agents, flavoring agents, stabilizers, tackifiers and the like.

For example, powders may be prepared by simply mixing the active ingredient of the present invention with a suitable pharmaceutically acceptable excipient such as lactose, starch, microcrystalline cellulose. Granules are the active ingredient of the present invention; Suitable excipients which are pharmaceutically acceptable; And a suitable pharmaceutically acceptable binder such as polyvinylpyrrolidone and hydroxypropylcellulose, followed by wet granulation using a solvent such as water, ethanol or isopropanol or dry granulation using a compressive force . Further, the tablet may be prepared by mixing the above granule with a suitable pharmaceutically acceptable salt such as magnesium stearate and then tableting it using a tablet machine.

The health functional food according to the present invention can be used as a food additive according to the present invention. For example, the above-mentioned substances may be added as it is, or may be appropriately used according to conventional methods such as being used in combination with other foods or other food ingredients.

The mixing amount of the active ingredient of the extract according to the present invention can be suitably determined according to the intended use (health or treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term intake for the purpose of health and hygiene or for health control, it may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of stability.

There is no restriction | limiting in particular in the kind of said food. Examples of the food to which the active substance according to the present invention may be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, Tea drinks, alcoholic beverages, and vitamin complexes, and the like in the usual sense includes all health foods.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in general beverages. Natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As a sweetener, natural sweeteners such as tautin and stevia extract, or synthetic sweeteners such as saccharin or aspartame may be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, it is used in various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated drinks Carbonating agent and the like. In addition, the material according to the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination.

Further, the present invention provides a method for preparing a microcrystalline cellulose, And (S2) centrifuging the obtained extract to obtain a supernatant. Preferably, ethanol is most suitable as the solvent. Accordingly, the present invention provides a process for producing a polymer electrolyte membrane, comprising: (S1) And (S2) centrifuging the obtained extract to obtain a supernatant. The present invention provides a method for enhancing the fatty acid oxidation activity through the extract of Chrysanthemum morifolium.

The extract according to the present invention is capable of promoting fatty acid oxidation and improving obesity, hyperlipidemia, insulin resistance or metabolic syndrome. Specifically, it inhibits the expression of SREBP-1c, FAS and ACC to inhibit the synthesis of fatty acids, and can also inhibit the expression of ACC and increase the expression of CPT-1, thereby promoting the oxidation of fatty acids.

BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments of the invention and, together with the description of the invention, It should not be construed as limited.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the cytotoxicity of the extract of Chrysanthemum morifolium according to the present invention. FIG.
FIG. 2 is a graph showing the change in the amount of accumulated fatty acid according to the addition of the extract of Chrysanthemum morifolium according to the present invention. FIG.
FIG. 3 is a photograph showing the change in the amount of accumulated fatty acid as a result of the addition of the hederock extract according to the present invention, using Oil Red O staining method.
FIG. 4 shows the results of analysis of the effects of the middendok extract according to the present invention on the expression of SREBP-1c, FAS, ACC-1 and CPT-1 proteins.

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

≪ Preparation of Midway extract >

Experimental material

We bought Rhododendrons as biologically from Garak Market in Seoul and Jeju Gangneung Fish Market. The dehydrated materials were removed and lyophilized. The dried samples were used as extraction samples while being frozen.

Extract preparation

The freeze-dried helix was repeatedly extracted three times at 100 ° C for 6 hours in a round flask equipped with a reflux condenser tube with vertical addition of 80% EtOH by 20 times volume (w / v) of the total weight. After extraction, the supernatant was collected by centrifugation (SUPRA 22K, HANIL, Korea) at 6000 rpm for 20 min and filtered (No 2C, WHATMAN, England). The obtained supernatant was collected and freeze-dried (PVTFD30R, ILSHINBIOBASE, Korea) And used as an analytical sample.

≪ Analysis method of the Midway extract >

Cell culture

The human normal hepatocyte HepG2 cells used in the experiment were distributed from the Korean Cell Line Bank. MEM (10% FBS, 100 units / mL of penicillin G sodium, 100 μg / mL of streptomycin sulfate) was cultured in 5% CO ₂ and 37 ° C incubator (MCO-15AC, SANYO, Japan) for cell culture. The cultures were seeded at a concentration of 5 × 10 ⁴ cells / well in a 96-well plate (Corning, USA). After 24 hours, 0.5 mM FAs (containing palate, oleate in proportions of 6: 4) And cultured for another 24 hours. Fatty acid accumulation was induced in the control group and that of the ethanol extract of midduk was added as an experimental group.

Toxicity measurement (MTT Assay)

MTT assay was performed to investigate the toxicity of the extract of Chrysanthemum morifolium to HepG2 cells. Cells were seeded at a concentration of 5 × 10 ⁴ cells / well in a 96-well plate (Corning, USA) and the cells were stabilized for 24 hrs. The cells were treated with 1000 μg / And reacted for 24 hours. After removing the culture medium, the cells were diluted 1/10 in MEM culture medium using EZ-Cytox Cell viability assay kit, incubated at 37 ° C for 1 hour, and the resulting formazan was measured for absorbance at 450 nm. The mean value and the standard error were obtained by three measurements.

Measurement of intracellular fatty acid accumulation (Oil Red O staining and quantification)

Oil Red O staining was performed to confirm accumulation of fatty acids in the cells. Fatty acid accumulation induction, fatty acid accumulation induction and Midway ethanol extract were added at concentrations of 100, 200 and 400 ug / mL, respectively. The cultured cells were washed with phosphate-buffered saline (PBS), treated with 50 μL of Oil Red O and stained at room temperature for 1 hour. The staining solution was then removed and washed with PBS. The stained cells were observed with a microscopic image (Olympus, Japan). For the quantification, 100 uL of isopropanol was added to the cells for staining and the absorbance was measured at 510 nm using a microplate reader (Thermo Scientific, Finland).

Analysis of protein expression (Western blot analysis)

Fatty acid accumulation induction, fatty acid accumulation induction, and micronutrient ethanol extract were added at concentrations of 100, 200 and 400 ug / mL, respectively. HepG2 cells were homogenized with a lysis buffer and homogenized with lysis buffer, and proteins were extracted. The samples were mixed with buffer, boiled for 5 minutes, and then cooled on ice. After electrophoresis in 10% SDS-polyacrylamide gel, the membrane was transferred to the membrane. The cells were blocked with a solution containing 5% BSA at room temperature for 1 hour. (1: 1000, Cell Signaling, USA), SREBP-1c (1: 600, Cell Signaling, USA), FAS and ACC , USA) was diluted in 5% skim milk and over-night at 4 ° C in a refrigerator. The next day, the cells were washed three times with TBST buffer for 10 minutes, and the secondary antibody was diluted 1: 5000 and reacted at room temperature for 2 hours. The cells were washed three times for 10 minutes with TBST buffer, and then reacted with ECL Plus (Amersham, USA) for 30 minutes and confirmed by X-ray film (Kodak, Japan).

Statistical processing

The mean and standard deviation of the results of this experiment were calculated using SPSS package program 18.0 for statistical analysis. The mean value analysis between two groups was performed by independent T test and significant difference test was performed at p <0.05 level. ) Was tested using Duncan's multiple comparison test.

&Lt; Analysis result of Midway extract >

Cytotoxicity evaluation results

As shown in FIG. 1, when the ethanol extract of Miedderd was treated at different concentrations, the value of the Miedderd ethanol extract was similar to that of the control group. That is, it was observed that there was no cytotoxicity depending on the concentration of the ethanol extract of middeck.

Evaluation results of fatty acid accumulation

Oil Red O staining method was used for easy observation of fatty acid accumulation in cells. The degree of accumulation of fatty acids in the cells can be easily observed by increasing the staining. As shown in FIG. 3, when the control group without fatty acid treatment was stained with red color, it was observed that the red color was significantly different from the control group treated with 0.5 mM FAs. In addition, 0.5mM FAs and staining of the experimental group treated with the concentration of each sample showed that the fatty acid accumulation was inhibited in a concentration dependent manner. FIG. 2 is a graph showing the amount of accumulated fatty acid quantitatively, showing that the fatty acid content of the experimental group treated with the Michelde ethanol extract was significantly lower than that of the fatty acid-treated group.

Analysis of protein expression

As shown in FIG. 4, the effect of the ethanol extract of middark on the expression of SREBP-1c, FAS and ACC-1 was inhibited in a concentration-dependent manner, and the expression of SREBP-1c, FAS and ACC- 1 expression was increased in a concentration-dependent manner. In other words, the ethanol extract of middeck inhibited the expression of SREBP-1c, inhibited the expression of FAS and ACC-1, and also increased the expression of CPT-1. These results indicate that the ethanol extract of middeck inhibits fatty acid accumulation and promotes fatty acid oxidation.

Claims (7)

Fatty acid oxidation promoting composition, characterized in that it comprises the extract as an active ingredient. The method of claim 1,
The midderb extract is a composition for promoting fatty acid oxidation, characterized in that the ethanol extract of midderm. A pharmaceutical composition for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, characterized in that it comprises an extract as an active ingredient. The method of claim 3,
The middera extract is a pharmaceutical composition for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, characterized in that the ethanol extract of middera. Health functional foods for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, characterized in that the extract as an active ingredient. The method of claim 5,
The middera extract is a dietary supplement for improving obesity, hyperlipidemia, insulin resistance syndrome or metabolic syndrome, characterized in that the ethanol extract of the middera. (S1) extracting the meddling with ethanol; And (S2) centrifuging the obtained extract to obtain a supernatant.

Images